Home › Lung Diseases › Alabama › Huntsville
Lung Diseases clinical trials in Huntsville, AL
3 studies for Lung Diseases are looking for participants at sites in and around Huntsville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease
RecruitingPhase 3
- University of Alabama at Birmingham, Huntsville Regional Medical Campus (HRMC), Huntsville
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
RecruitingPhase 2
- Clearview Cancer Institute (Crestwood), Huntsville
- Clearview Cancer Institute, Huntsville
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- Clearview Cancer Institute, Huntsville
About Lung Diseases
Lung diseases are disorders or infections that affect the lungs and cause breathing problems. Some can lead to respiratory failure. Find out more about prevention, living with lung diseases, and treatment.
More about Lung Diseases on MedlinePlus
Lung Diseases trials in other cities
- Houston, TX15 studies
- Boston, MA14 studies
- Durham, NC13 studies
- New York City, NY12 studies
- Pittsburgh, PA11 studies
- Dallas, TX10 studies
- Miami, FL10 studies
- Columbus, OH10 studies
- Nashville, TN10 studies
- Los Angeles, CA10 studies
- Washington, DC10 studies
- Ann Arbor, MI10 studies
Other studies in Huntsville
- Cardiovascular Disease8 studies
- Obesity7 studies
- Coronary Artery Disease6 studies
- Heart Failure6 studies
- Major Depressive Disorder6 studies
- Type 2 Diabetes6 studies
- Depression6 studies
- Atherosclerosis5 studies
- Overweight5 studies
- Aortic Valve Stenosis4 studies
- Chronic Kidney Disease4 studies
- Heart Attack3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.